Analyzing Dynavax Technologies Corp (DVAX) After Recent Trading Activity

Daniel Torres

In a filing, Dynavax Technologies Corp revealed its President & COO Novack David F unloaded Company’s shares for reported $0.46 million on Dec 24 ’25. In the deal valued at $15.49 per share,30,000 shares were sold. As a result of this transaction, Novack David F now holds 111,451 shares worth roughly $1.72 million.

Then, DAVID NOVACK bought 30,000 shares, generating $464,700 in total proceeds.

Before that, Myers Scott Dunseth bought 3,800 shares. Dynavax Technologies Corp shares valued at $41,116 were divested by the Director at a price of $10.82 per share. As a result of the transaction, Myers Scott Dunseth now holds 35,004 shares, worth roughly $0.54 million.

Goldman downgraded its Dynavax Technologies Corp [DVAX] rating to a Sell from a a Neutral in a research note published on February 11, 2025; the price target was decreased to $12 from $15. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early February with a ‘”a Neutral”‘ rating. JMP Securities began covering DVAX with “Mkt outperform” recommendation on September 27, 2022.

Price Performance Review of DVAX

On Monday, Dynavax Technologies Corp [NASDAQ:DVAX] saw its stock unchanged to $15.41. Over the last five days, the stock has gained 0.20%. Dynavax Technologies Corp shares have risen nearly 20.11% since the year began. Nevertheless, the stocks have risen 0.20% over the past one year.

How much short interest is there in Dynavax Technologies Corp?

A steep rise in short interest was recorded in Dynavax Technologies Corp stocks on 2025-12-15, dropping by -1.43 million shares to a total of 12.29 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 13.72 million shares. There was a decline of -11.66%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on August 06, 2021 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $19 price target.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.